EN DE
Watch Sensorion SA for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

Sensorion SA (ALSEN) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of Sensorion SA stock €6.94, price €7.62, that is 9.0% below the price, quality 38 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare FR · ISIN FR0012596468

SS Sensorion SA logo Thin data Nov 16, 2026

Sensorion SA

ALSEN · PA

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Low debt 
Fair value €6.94 · Fairly valued 
Mixed Growth (revenue 5y +22.0 %/yr in EUR) 
Mixed vs. peers (4/8) 
Quality 38/100 
Falling price (downtrend) 
Negative free cash flow 
Narrow moat 10/100 · thin data
Thin data 
Estimate
Watch Sensorion SA for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

€109.00 €5.64 Fair Value €6.94 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range €5.64 – €109.00 · fair‑value band €5.20 – €8.67 · the €7.62 price screens above the €6.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow Sensorion in your weekly email

Every Wednesday you see whether Sensorion is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sensorion SA, a biotechnology company, engages in the development of novel therapies to restore, treat, and prevent hearing loss disorders in France.

Show moreShow less

The company develops SENS-501, a dual AAV vector gene therapy development product for restoring hearing in patients with mutations in OTOF gene in Phase 1/2 clinical trials; and SENS-601, a candidate for the treatment of hearing loss caused by mutations of the GJB2 gene in preclinical studies.

It is also developing SENS-40, a small molecule in Phase 2b clinical trials to treat sudden sensorineural hearing loss; prevention of residual hearing loss following cochlear implantation in Phase 2a clinical trials; and prevention of cisplatin-induced ototoxicity in Phase 2a clinical trials.

The company was incorporated in 2009 and is headquartered in Montpellier, France.

Stock analysis

Sensorion SA (ALSEN) currently trades at €7.62, while our estimate is €6.94, so the stock looks roughly fairly valued today (gap 9.9%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: €5.20 (bear) to €8.67 (bull), the price of €7.62 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Sensorion SA reported revenue of €0 in FY2025 versus €4.3M in FY2021. Reported net income was −€29.4M in FY2025.

Key figures

Market cap €79.4M Micro · P/S ratio 14.6 · EPS (TTM) €−4.65 · Return on equity −49.3% · Return on assets (EBIT) −49.6% (5-year average) · Operating margin −803% · Revenue (TTM) €6.2M · Revenue growth (YoY) +14.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 78% below its 52-week high and 35% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −9%, ALSEN screens richer than that median.

Fair Value

Bear €5.20 Fair Value €6.94 Bull €8.67
Price €7.62 · Downside -9.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 38/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 4
Are margins and returns getting better?
Cashflow 29
Do the profits arrive as real cash?
Financial strength 77
Debt, balance sheet and risk of trouble
Investment 15
Does it invest with discipline instead of growing at any price?
Low Volatility 48
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+16.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.0%
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+164.9%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−542.1% (2019) → −426.9% (2024)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch ALSEN, get fair value alerts →

Compare Sensorion SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 851 stocks

Beats the industry median on 3/6 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 38 · Below median
Fair Value upside −9.0% · Above median
Profitability
Return on assets −50.8% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 14.7% · Above median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 1.78× · Cheaper than median
P/S (12 months) 12.90× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)21 · sector 2
FUTURE (revenue growth)74 · sector 37
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)0 · sector 21

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $945.53 $1,275 +35% vs ALSEN
Vertex Pharmaceuticals Incorporated VRTX $536.45 $587.62 +10% vs ALSEN
Samsung Biologics Co 207940 1,375,000 KRW 1,502,600 KRW +9% vs ALSEN
argenx SE ARGX $941.25 $908.40 −3% vs ALSEN
CSL Limited CSL A$199.85 A$186.49 −7% vs ALSEN
Moderna, Inc MRNA $196.79 $135.64 −31% vs ALSEN
BeOne Medicines AG 6160 HK$242.60 HK$152.92 −37% vs ALSEN
Revolution Medicines, Inc RVMD $159.82 $83.12 −48% vs ALSEN
Celltrion, Inc 068270 215,000 KRW 74,945 KRW −65% vs ALSEN
Royalty Pharma plc RPRX $68.67 $19.01 −72% vs ALSEN

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sensorion SA: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sensorion SA Fair Value". https://www.fairvalue-calculator.com/stock/ALSEN

Frequently asked questions

Is Sensorion SA (ALSEN) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is €6.94 versus a price of €7.62, about 9% lower (fairly valued).
What is the fair value of ALSEN?
Our estimate for Sensorion SA is €6.94 (as of Nov 16, 2026), built from audited fundamentals. The current price: €7.62.
What is the quality score of ALSEN?
Sensorion SA has a Quality Score of 38/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sensorion SA (ALSEN)?
We do not set a price target; the yardstick is our estimate of €6.94 (as of Nov 16, 2026). Cautious scenario €5.20, optimistic scenario €8.67. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Sensorion SA stock forecast for 2026?
Our estimate puts fair value at €6.94, about 9% lower versus a price of €7.62 (fairly valued). Cautious scenario €5.20, optimistic scenario €8.67. The calculation is refreshed regularly with new filings.
What is the revenue of Sensorion SA (ALSEN)?
Sensorion SA reported trailing-twelve-month revenue of about €6.2M (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of Sensorion SA (ALSEN)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sensorion SA it is €6.94 per share (as of Nov 16, 2026), against a price of €7.62.
Is Sensorion SA stock overvalued or undervalued in 2026?
As of Nov 16, 2026, ALSEN trades above its calculated fair value: price €7.62, fair value €6.94, a gap of about −9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ALSEN?
No. The price is what the market pays today (€7.62); the fair value is what the company's own numbers justify (€6.94). For Sensorion SA the two are €0.6840 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sensorion SA worth?
The market values Sensorion SA at about €79.4M (market capitalisation, as of Nov 16, 2026). Per share that is €7.62; our models calculate a fair value of €6.94 per share.
What do the bullish and bearish scenarios say about ALSEN?
Our models span a range for Sensorion SA: cautious scenario €5.20, base €6.94, optimistic €8.67 per share (as of Nov 16, 2026, price €7.62). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sensorion SA (ALSEN)?
Balance-sheet figures for Sensorion SA (as of Nov 16, 2026): return on equity −49.3%. They feed the Quality Score of 38/100, which measures business quality independently of the share price.
How far is ALSEN from its 52-week high?
Sensorion SA trades at €7.62, about 78% below its 52-week high of €35.00 and 35% above the low of €5.64 (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of €6.94 is for.
Which stocks are comparable to Sensorion SA?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sensorion SA stock attractive at the current price?
The data as of Nov 16, 2026: price €7.62, calculated fair value €6.94 (−9%), Quality Score 38/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. Sensorion SA itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sensorion SA (ALSEN)?
The closing price on Nov 19, 2026 was €7.62. Our estimate is €6.94, about 9% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sensorion SA right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Sensorion SA

How large is the market capitalisation of Sensorion SA (ALSEN)?
The market capitalisation of Sensorion SA is €79.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sensorion SA (ALSEN)?
The price-to-sales ratio of Sensorion SA is 14.6 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sensorion SA (ALSEN)?
Earnings per share at Sensorion SA are €−4.65. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Sensorion SA (ALSEN)?
The return on equity (ROE) of Sensorion SA is −49.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sensorion SA (ALSEN)?
On an EBIT basis the return on assets of Sensorion SA is −49.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sensorion SA (ALSEN)?
The operating margin of Sensorion SA is −803% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sensorion SA (ALSEN)?
Revenue at Sensorion SA is growing 14.7% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sensorion SA (ALSEN) generate?
The free cash flow of Sensorion SA is −€27.6M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Sensorion SA (ALSEN) hold?
Sensorion SA holds more cash than debt, €19.4M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Sensorion SA in the live analysis

One click puts Sensorion SA on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.